Vanda Pharmaceuticals Inc. (VNDA) Receives $36.00 Average Target Price from Analysts

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has received an average rating of “Hold” from the thirteen analysts that are presently covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell rating, six have issued a hold rating and four have given a buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $33.67.

Several brokerages have recently commented on VNDA. BidaskClub downgraded Vanda Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, January 24th. ValuEngine downgraded Vanda Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, February 4th. Cantor Fitzgerald downgraded Vanda Pharmaceuticals from an “overweight” rating to a “neutral” rating and reduced their target price for the stock from $38.00 to $30.00 in a report on Wednesday, February 6th. Stifel Nicolaus reissued a “buy” rating on shares of Vanda Pharmaceuticals in a report on Wednesday, February 6th. Finally, Oppenheimer reduced their target price on Vanda Pharmaceuticals from $29.00 to $21.00 in a report on Thursday, February 14th.

In related news, CFO James Patrick Kelly sold 4,976 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $20.15, for a total value of $100,266.40. Following the completion of the transaction, the chief financial officer now owns 218,497 shares in the company, valued at approximately $4,402,714.55. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Mihael Hristos Polymeropoulos sold 38,166 shares of the business’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $19.41, for a total transaction of $740,802.06. Following the completion of the transaction, the chief executive officer now owns 1,217,136 shares of the company’s stock, valued at approximately $23,624,609.76. The disclosure for this sale can be found here. Insiders sold a total of 59,274 shares of company stock worth $1,164,127 over the last three months. 8.20% of the stock is owned by company insiders.

Hedge funds have recently bought and sold shares of the stock. Metropolitan Life Insurance Co. NY raised its position in Vanda Pharmaceuticals by 356.6% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 17,187 shares of the biopharmaceutical company’s stock worth $449,000 after purchasing an additional 13,423 shares during the last quarter. Algert Global LLC bought a new position in Vanda Pharmaceuticals in the 4th quarter worth approximately $1,991,000. First Manhattan Co. raised its position in Vanda Pharmaceuticals by 13.8% in the 4th quarter. First Manhattan Co. now owns 939,374 shares of the biopharmaceutical company’s stock worth $24,545,000 after purchasing an additional 113,999 shares during the last quarter. Dimensional Fund Advisors LP bought a new position in Vanda Pharmaceuticals in the 3rd quarter worth approximately $5,965,000. Finally, Neuberger Berman Group LLC raised its position in Vanda Pharmaceuticals by 51.7% in the 3rd quarter. Neuberger Berman Group LLC now owns 45,500 shares of the biopharmaceutical company’s stock worth $1,044,000 after purchasing an additional 15,500 shares during the last quarter. Hedge funds and other institutional investors own 98.57% of the company’s stock.

Shares of VNDA traded up $0.23 on Thursday, hitting $16.35. The company’s stock had a trading volume of 513,081 shares, compared to its average volume of 853,177. The company has a market capitalization of $853.78 million, a P/E ratio of 34.06, a PEG ratio of 10.96 and a beta of 0.44. Vanda Pharmaceuticals has a fifty-two week low of $13.66 and a fifty-two week high of $33.44.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.01) EPS for the quarter, missing the consensus estimate of $0.07 by ($0.08). The business had revenue of $47.71 million during the quarter, compared to analyst estimates of $51.74 million. Vanda Pharmaceuticals had a return on equity of 8.07% and a net margin of 10.92%. The firm’s revenue was up 9.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.14 earnings per share. Sell-side analysts anticipate that Vanda Pharmaceuticals will post 0.1 EPS for the current fiscal year.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.

Recommended Story: Price to Earnings Ratio (PE)

Analyst Recommendations for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.